Insider Transactions in Q4 2021 at Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
Matthew Buten Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,323
-50.58%
|
$866,251
$137.81 P/Share
|
|
Dec 31
2021
|
Matthew Buten Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+50.0%
|
-
|
|
Dec 20
2021
|
Julia P Gregory |
SELL
Open market or private sale
|
Direct |
12,000
-100.0%
|
$1,500,000
$125.0 P/Share
|
|
Dec 20
2021
|
Julia P Gregory |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$276,000
$23.63 P/Share
|
|
Dec 20
2021
|
George C. Clark VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,915
-18.86%
|
$235,545
$123.84 P/Share
|
|
Dec 15
2021
|
Elyse Stock Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,919
-43.36%
|
$2,301,495
$105.8 P/Share
|
|
Dec 15
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,919
+33.14%
|
$328,785
$15.81 P/Share
|
|
Dec 14
2021
|
Elyse Stock Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,939
-48.17%
|
$728,595
$105.02 P/Share
|
|
Dec 14
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,939
+21.79%
|
$104,085
$15.81 P/Share
|
|
Dec 10
2021
|
James Engelhart Strategic Advisor |
SELL
Open market or private sale
|
Direct |
35,000
-32.68%
|
$3,570,000
$102.85 P/Share
|
|
Dec 10
2021
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+43.11%
|
-
|
|
Nov 29
2021
|
Declan Doogan |
SELL
Open market or private sale
|
Direct |
24,525
-1.38%
|
$2,746,800
$112.83 P/Share
|
|
Nov 26
2021
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,318
-18.58%
|
$266,570
$115.55 P/Share
|
|
Nov 26
2021
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+28.62%
|
-
|
|
Nov 25
2021
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,075
-16.72%
|
$583,625
$115.55 P/Share
|
|
Nov 25
2021
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,950
+26.51%
|
-
|
|
Nov 25
2021
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,715
-13.28%
|
$197,225
$115.55 P/Share
|
|
Nov 25
2021
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+22.27%
|
-
|
|
Nov 25
2021
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,738
-15.19%
|
$199,870
$115.55 P/Share
|
|
Nov 25
2021
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+24.69%
|
-
|
|
Nov 25
2021
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
1,305
-12.89%
|
$150,075
$115.55 P/Share
|
|
Nov 25
2021
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+22.85%
|
-
|
|
Nov 25
2021
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,599
-17.64%
|
$183,885
$115.55 P/Share
|
|
Nov 25
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,375
+27.13%
|
-
|
|
Nov 25
2021
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-12.59%
|
$56,580
$115.55 P/Share
|
|
Nov 25
2021
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+24.23%
|
-
|
|
Nov 25
2021
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+13.1%
|
-
|
|
Nov 23
2021
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,885
+21.71%
|
$315,665
$29.17 P/Share
|
|
Nov 23
2021
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,915
+20.4%
|
$61,280
$32.42 P/Share
|
|
Nov 16
2021
|
Declan Doogan |
SELL
Open market or private sale
|
Direct |
37,740
-1.37%
|
$4,377,840
$116.82 P/Share
|
|
Nov 16
2021
|
Declan Doogan |
BUY
Exercise of conversion of derivative security
|
Direct |
559,000
+8.75%
|
$12,857,000
$23.42 P/Share
|
|
Nov 15
2021
|
John W Childs |
BUY
Exercise of conversion of derivative security
|
Direct |
474,200
+2.25%
|
$10,906,600
$23.42 P/Share
|
|
Nov 10
2021
|
John W Childs |
BUY
Open market or private purchase
|
Direct |
5,000
+0.1%
|
$615,000
$123.03 P/Share
|